Shanghai Fosun Pharmaceutical Group Co Ltd (600196) — Cash Flow Quality Index
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Cash Flow Quality Index of 2.83x as of December 2025. Operating cash flow of CN¥2.40 Billion exceeds net income of CN¥847.27 Million, indicating high earnings quality where cash backs reported profits. Explore 600196 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Shanghai Fosun Pharmaceutical Group Co Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for Shanghai Fosun Pharmaceutical Group Co Ltd across 28 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Shanghai Fosun Pharmaceutical Group Co L cash flow conversion.
Annual Cash Flow Quality Index for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year earnings quality comparison for Shanghai Fosun Pharmaceutical Group Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.78x | CN¥6.01 Billion | CN¥3.37 Billion | ▲ +39.8% |
| 2024 | 1.27x | CN¥4.48 Billion | CN¥3.51 Billion | ▼ -30.3% |
| 2023 | 1.83x | CN¥4.36 Billion | CN¥2.39 Billion | ▲ +71.1% |
| 2022 | 1.07x | CN¥4.22 Billion | CN¥3.95 Billion | ▲ +34.9% |
| 2021 | 0.79x | CN¥3.95 Billion | CN¥4.99 Billion | ▲ +20.9% |
| 2020 | 0.65x | CN¥2.58 Billion | CN¥3.94 Billion | ▼ -23.9% |
| 2019 | 0.86x | CN¥3.22 Billion | CN¥3.74 Billion | ▼ -11.9% |
| 2018 | 0.98x | CN¥2.95 Billion | CN¥3.02 Billion | ▲ +35.7% |
| 2017 | 0.72x | CN¥2.58 Billion | CN¥3.59 Billion | ▲ +9.9% |
| 2016 | 0.66x | CN¥2.11 Billion | CN¥3.22 Billion | ▲ +16.0% |
| 2015 | 0.56x | CN¥1.62 Billion | CN¥2.87 Billion | ▲ +11.5% |
| 2014 | 0.51x | CN¥1.20 Billion | CN¥2.37 Billion | ▲ +20.1% |
| 2013 | 0.42x | CN¥1.01 Billion | CN¥2.40 Billion | ▲ +16.5% |
| 2012 | 0.36x | CN¥665.52 Million | CN¥1.84 Billion | ▲ +58.2% |
| 2011 | 0.23x | CN¥316.65 Million | CN¥1.38 Billion | ▲ +12.5% |
| 2010 | 0.20x | CN¥203.36 Million | CN¥1.00 Billion | ▲ +99.1% |
| 2009 | 0.10x | CN¥261.87 Million | CN¥2.56 Billion | ▼ -66.7% |
| 2008 | 0.31x | CN¥233.04 Million | CN¥760.93 Million | ▲ +60.8% |
| 2007 | 0.19x | CN¥131.48 Million | CN¥690.19 Million | ▼ -69.8% |
| 2006 | 0.63x | CN¥184.91 Million | CN¥292.83 Million | ▼ -20.2% |
| 2005 | 0.79x | CN¥188.35 Million | CN¥237.94 Million | ▲ +8.9% |
| 2004 | 0.73x | CN¥205.10 Million | CN¥282.09 Million | ▲ +44.4% |
| 2003 | 0.50x | CN¥150.14 Million | CN¥298.18 Million | ▼ -20.5% |
| 2002 | 0.63x | CN¥102.47 Million | CN¥161.75 Million | ▲ +31.2% |
| 2001 | 0.48x | CN¥68.15 Million | CN¥141.08 Million | ▼ -52.6% |
| 2000 | 1.02x | CN¥138.43 Million | CN¥135.79 Million | ▲ +152.0% |
| 1999 | 0.40x | CN¥38.20 Million | CN¥94.43 Million | ▼ -60.5% |
| 1998 | 1.03x | CN¥66.55 Million | CN¥64.93 Million | — |